Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mutaflor for UTI prevention in children
NCT04608851Phase 4Unknown
- Sponsor
- University of Oulu
- Start
- Jan 2021
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of escherichia coli nissle 1917 in urinary tract infection (UTI), sponsored by University of Oulu. Primary endpoint: Recurrence of urinary tract infections at 6 months. Status: unknown.
02
Drugs
escherichia coli nissle 1917
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT04608851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608851.